Reported results
- Total revenue was $12.9 million for the three months ended September 30, 2026.
- Research and development expenses were $26.1 million for the three months ended September 30, 2026.
- General and administrative expenses totaled $8.8 million for the three months ended September 30, 2026.
- Net loss for the three months ended September 30, 2026, was $23.7 million, or a loss of $0.81 per diluted common share.
- Cash and marketable securities totaled $194.5 million at September 30, 2026.
Notes
A portion (54.5%) of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET/MAVIRET is paid to OMERS pursuant to a royalty sale transaction treated as debt for financial reporting purposes.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
